Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Redasemtide trifluoroacetate by Shionogi for Dilated Cardiomyopathy: Likelihood of Approval
Redasemtide trifluoroacetate is under clinical development by Shionogi and currently in Phase II for Dilated Cardiomyopathy. According to GlobalData, Phase...